Silgals R M, Ahlgren J D, Neefe J R, Rothman J, Rudnick S, Galicky F P, Schein P S
Cancer. 1984 Nov 15;54(10):2257-61. doi: 10.1002/1097-0142(19841115)54:10<2257::aid-cncr2820541032>3.0.co;2-c.
Twenty-one patients with metastatic colorectal cancer were treated with high-dose intravenous interferon alpha-2 (30-50 X 10(6) units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two subjects, disease remained stable for 3 and 7 months, respectively. Toxicity was substantial and a de-escalation of dose was frequently required. Fevers, gastrointestinal symptoms, fatigue, leukopenia, and elevated serum transaminases were common. High-dose interferon was found to be ineffective in the treatment of metastatic colorectal cancer. A daily dose of 50 X 10(6) units/m2 was greater than the maximum tolerated dose in this group of patients.
21例转移性结直肠癌患者接受了大剂量静脉注射α-2干扰素治疗（30 - 50×10⁶单位/平方米），每日1次，连续5天。每2至3周重复一个疗程。15例可评估患者中未见肿瘤反应。有2例患者病情分别稳定了3个月和7个月。毒性反应严重，常需降低剂量。发热、胃肠道症状、疲劳、白细胞减少和血清转氨酶升高很常见。发现大剂量干扰素治疗转移性结直肠癌无效。每日剂量50×10⁶单位/平方米超过了该组患者的最大耐受剂量。
